Drug Profile
Research programme: anti-cancer therapeutics - Inflection Biosciences/AUM Biosciences
Alternative Names: IBL-100 series; IBL-300 series; IBL-301Latest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator Spanish National Cancer Research Centre
- Developer Inflection Biosciences; Multiple Myeloma Research Foundation; Trinity College Dublin; University of Sydney; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Proto oncogene proteins c pim 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chronic lymphocytic leukaemia; Haematological malignancies; Head and neck cancer; Multiple myeloma; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Solid-tumours in Ireland (PO)
- 28 Feb 2023 No recent reports of development identified for preclinical development in Haematological-malignancies in Australia (PO)
- 28 Jan 2023 No recent reports of development identified for preclinical development in Chronic-lymphocytic-leukaemia(Combination therapy) in Ireland (PO)